Curian Capital Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Curian Capital reduced its stake in Pfizer by 63.15% during the most recent quarter end. The investment management company now holds a total of 270,733 shares of Pfizer which is valued at $8,855,676 after selling 463,954 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 25, 2016.Pfizer makes up approximately 0.65% of Curian Capital’s portfolio.

Pfizer opened for trading at $32.56 and hit $33 on the upside on Monday, eventually ending the session at $32.8, with a gain of 0.28% or 0.09 points. The heightened volatility saw the trading volume jump to 3,80,66,813 shares. Company has a market cap of $202,840 M.

Other Hedge Funds, Including , Excalibur Management Corp boosted its stake in PFE in the latest quarter, The investment management firm added 313 additional shares and now holds a total of 187,123 shares of Pfizer which is valued at $6,120,793. Pfizer makes up approx 5.46% of Excalibur Management Corp’s portfolio.Eastern Bank reduced its stake in PFE by selling 711 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 64,557 shares of PFE which is valued at $2,098,103. Pfizer makes up approx 0.17% of Eastern Bank’s portfolio.Palisade Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 50,149 shares of Pfizer which is valued at $1,629,843. Pfizer makes up approx 0.32% of Palisade Asset Management’s portfolio.Kanaly Trust Co reduced its stake in PFE by selling 462 shares or 6.35% in the most recent quarter. The Hedge Fund company now holds 6,809 shares of PFE which is valued at $221,293. Pfizer makes up approx 0.04% of Kanaly Trust Co’s portfolio.Salem Capital Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 1,375 additional shares and now holds a total of 211,919 shares of Pfizer which is valued at $6,887,368. Pfizer makes up approx 3.80% of Salem Capital Management Inc’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.